UHN-Toronto General Hospital

Toronto, Ontario M5G2C4

2 studies enrolling now · 9 studies all time

What they study most

Acute Myocardial Infarction (AMI), Cardiovascular Risk, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Heart Failure, Heart Failure With Reduced Ejection Fraction, Hepatitis, Hepatitis B, Liver Diseases, Obesity, Sickle Cell Disease, Type 2 Diabetes

Studies at this site

• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction — Recruiting now
• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Recruiting now
• ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack — Recruiting now
• A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo — Completed
• A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) — Completed
• A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes — Completed
• An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection — Stopped early
• A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease — Completed
• Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT) — Stopped early